Novartis (NVS) has reached new all-time highs, with shares up almost 50% in the past year. The company’s CEO predicts limited tariff exposure by mid-2026, boosting investor confidence. Valued at $310.8 billion, Novartis specializes in pharmaceuticals like Entresto and Cosentyx, with a 100% “Buy” opinion from Barchart.

Novartis hit a record high of $148.38 on Jan. 26, with a Weighted Alpha of +45.01. The stock gained 48.42% in the last 52 weeks and maintains a 100% “Buy” opinion. With a Trend Seeker “Buy” signal, Novartis is trading at $148.38, showing strong technical momentum and relative strength index at 73.14.

Novartis’ market capitalization is $310.8 billion, with a 16.24x P/E ratio. Analysts project earnings to rise by 13.32% in 2025 and 2.94% in 2026. Rated a “Moderate Buy” with price targets from $112 to $162.50, Novartis has low short interest at 0.28% of float. The stock has seen 6 new highs and a 6.61% increase in the past month.

Novartis continues to impress with share-price growth and strong technical momentum. CEO Narasimhan’s comments on limited tariff exposure by mid-2026 have further fueled investor optimism. As pharmaceutical exports are a significant portion of EU exports, Novartis remains well-positioned for future success amidst global trade uncertainties.

Read more at Yahoo Finance: Is This Pharmaceutical Giant a Winning Tariff-Proof Stock to Buy for 2026?